Jade Biosciences, Inc. 8-K

What Happened

• Jade Biosciences, Inc. announced on March 31, 2026 that its Board approved the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan (the "2026 Inducement Plan") and filed an 8-K to report the action. The Board adopted the plan without stockholder approval under Nasdaq Listing Rule 5635(c)(4).

Key Details

• The Board initially reserved 1,750,000 shares of common stock for awards under the 2026 Inducement Plan.
• The plan’s terms are substantially similar to the company’s 2025 Stock Incentive Plan, except (1) incentive stock options (ISOs) may not be issued under the Inducement Plan, and (2) awards may only be made to eligible recipients under applicable Nasdaq rules.
• Under Nasdaq Rule 5635(c)(4), awards under this inducement plan may be granted only to employees who were not previously employees or directors (or who return after a bona fide period of non-employment) and only if the grant is material to inducement of employment.
• The company intends to file the full plan text and the forms of stock option and restricted stock unit agreements as exhibits to its Form 10-Q for the quarter ended March 31, 2026.

Why It Matters

• This action gives the company a reserved pool of equity (1.75M shares) to attract new hires through stock-based compensation without seeking immediate shareholder approval, per Nasdaq rules. For investors, key points are the size of the share reserve, the limitation on ISOs, and the company’s use of inducement awards as a hiring tool — all of which can affect share dilution and executive/employee retention cost.